****

As of April 2026, the global cannabis industry has transitioned from its early explosive growth phase into a more mature, albeit challenged, consumer goods sector. In the dominant U.S. market, the industry experienced its first year-over-year revenue decline in 2025 due to oversupply, aggressive price compression, and competition from the illicit market. However, modest growth is projected for 2026, supported by product innovation, steady consumer demand, and the potential for federal policy shifts. Internationally, expansion continues in medical cannabis, with slower progress on adult-use markets outside North America.

### U.S. Legalization Landscape
Adult-use (recreational) cannabis is legal in **24 states**, the District of Columbia, and Guam for adults 21 and older. The states include Alaska, Arizona, California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oregon, Rhode Island, Vermont, Virginia, and Washington.

Medical cannabis programs operate in **40–42 states** plus D.C., with regulated sales available in most. Approximately 79% of Americans now live in a jurisdiction with some form of legal cannabis access, and the country boasts nearly 15,000 dispensaries. Public support for legalization remains strong, with declining stigma and mainstream adoption: daily or near-daily cannabis use has surpassed daily alcohol consumption in prevalence among certain demographics.

Virginia, which legalized adult-use possession in 2021, is advancing toward regulated recreational sales, with expectations of fuller implementation in 2026.

### Market Size and Performance in the U.S.
Projections for 2026 U.S. cannabis revenue vary depending on the source and scope:

– Statista estimates total revenue approaching **$47 billion**, with an annual growth rate of about 3.36% leading toward $55.4 billion by 2030.
– Whitney Economics, a leading cannabis-focused research firm, forecasts **$30.5 billion** in legal regulated revenues for 2026—a 4.9% increase from the 2025 figure, marking a rebound after the industry’s first annual decline (estimated at roughly $29–31.5 billion in 2025).

The 2025 contraction was driven by widespread oversupply, falling wholesale prices (particularly for undifferentiated flower), high state taxes, and competition from illicit and hemp-derived alternatives. Despite lower revenues, unit volumes remained relatively stable in many markets. Top-performing states in early 2026 data include California, Michigan, Florida (medical), New York, Illinois, and Massachusetts.

Flower continues to dominate sales (around 44%), followed by vapes, concentrates, and edibles. Faster-growing segments include cannabis beverages, pre-rolls, and premium or convenient formats. The industry supports approximately 425,000 full-time equivalent jobs and generates significant tax revenue, though economic multipliers show that every $10 spent in dispensaries creates broader activity of about $18.

A “discount economy” persists, with heavy promotions, loyalty programs, and price deflation pressuring margins, especially for smaller operators. Consolidation is evident: the number of active cannabis business licenses has declined by about 13% over the past two years as companies focus on efficiency and scale.

### Federal Outlook
Cannabis remains classified as a **Schedule I** substance under federal law, creating ongoing conflicts with state programs—particularly around taxes (Section 280E), banking, and interstate commerce.

In December 2025, President Trump issued an executive order directing the Department of Justice and DEA to expedite rescheduling cannabis to **Schedule III**, which would acknowledge accepted medical use, ease certain tax burdens, expand research opportunities, and potentially improve banking access. As of mid-April 2026, the process remains ongoing, with the administration reportedly “slow-walking” aspects of implementation. No final rulemaking has been completed, and potential delays or litigation could extend the timeline.

Rescheduling would not federally legalize recreational use but is widely viewed as a critical catalyst for investment, mergers and acquisitions, and improved profitability across the sector.

### Global Perspective
The global legal cannabis market in 2026 is estimated in a broad range, with projections varying from around **$25–52 billion** (or higher depending on whether cultivation and related activities are included). North America continues to dominate, accounting for roughly 70% or more of regulated activity.

– **Canada**: A mature adult-use market focused on operational efficiency, exports, and stabilization.
– **Europe**: Germany’s partial commercialization following 2024 decriminalization offers potential growth, though retail rollout faces hurdles. Medical cannabis is expanding in several countries.
– **Other regions**: Australia is scaling medical access; South America sees growing patient numbers (e.g., in Brazil); the Asia-Pacific region shows strong long-term trajectory in some forecasts.

Key global drivers include medical applications for pain management, anxiety, sleep, and reducing opioid reliance, alongside innovation in beverages and high-THC premium products.

### Key Trends, Challenges, and Opportunities
**Challenges**:
– Persistent oversupply and price compression, particularly in flower.
– Regulatory fragmentation, high taxes, and licensing restrictions.
– Limited banking and capital access until federal reforms advance.
– Competition from the unregulated illicit market and hemp-derived intoxicating cannabinoids.

**Opportunities**:
– Product diversification, including microdosing, functional beverages, and wellness-oriented formats.
– Demographic shifts: increasing participation from women, seniors, and wellness-focused consumers.
– Potential federal tailwinds from rescheduling and research expansion.
– International export potential and vertical integration into higher-margin, pharmaceutical-grade products.

### Outlook
In 2026, the cannabis industry is no longer a speculative “gold rush” but a maturing sector characterized by single-digit growth in established markets, operational consolidation, and cautious optimism. Efficient operators with strong branding, value propositions, and innovation pipelines are best positioned to thrive. Long-term upside remains tied to policy normalization at the federal level and continued international expansion.

While headwinds from oversupply and regulation persist, the combination of sustained consumer demand, declining stigma, and the prospect of federal reform suggests a pathway toward greater stability and profitability in the years ahead. The industry’s ability to adapt to a more competitive, consumer-driven environment will determine its trajectory beyond 2026.